<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

From Assay Development to Product Supply For COVID-19, Our Laboratories Are Here to Support

Posted by MD Biosciences on Apr 14, 2020 2:26:14 PM

A message from our laboratories to yours: during these times of economic and personal hardship, we want to extend our sincerest support and hope you are keeping well. 

Read More

Topics: Cytokines, assays, drug development, clinical research, Biotechnology, COVID-19

The Epigenome Has Made Its Debut

Posted by MD Biosciences on Sep 12, 2016 10:20:35 AM

In its 2015 “Year-in-Review”, Science News declared the “Epigenome” has made its “debut”. Why? Because epigenetic alterations; including acetylation, phosphorylation and methylation have been found to be a means by which genes can be regulated post translation.

While not new, numerous clinical studies have recently been published highlighting the important role methylation plays in epigenetic alterations.

Published findings include:

  • Mutations in the DNA methyltransferase 3A gene (DNMT3A) in transgenic mice supports clinical findings of clonal dominance occurring in aging populations.
  • A poor prognosis in acute myeloid leukemia (AML) is associated with DNMT3A mutations.
  • Presence of DNMT3A mutations is associated with poor prognosis in adult T-cell acute lymphoblastic leukemia (T-ALL).
  • Hypomethylation (due to loss of the enzymatic activity in the DNMTAs) and Hypermethylation (specifically in the promoter region) have both been observed in malignances.
Read More

Topics: Biomarkers, methylation, assays, epigenomic